ONCY (Oncolytics Biotech) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


ONCY Oncolytics Biotech Inc ONCY
31 GF Score
Price $0.92
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Oncolytics Biotech's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ONCY vs ALPS, KLRS, BDTX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Oncolytics Biotech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Margin of Safety % (DCF Earnings Based) falls into.


ONCY
31GF Score
Oncolytics Biotech Inc ONCY
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
31GF Score

Get the complete analysis for ONCY

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price